Takako Inoue

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1821569/publications.pdf

Version: 2024-02-01

26 622 11 24 papers citations h-index g-index

27 27 27 942 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Bile acid dysmetabolism in the gutâ€microbiotaâ€liver axis under hepatitis C virus infection. Liver International, 2022, 42, 124-134.	1.9	11
2	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. PLoS ONE, 2022, 17, e0263844.	1.1	5
3	Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB coreâ€related antigen assay. Hepatology Research, 2022, 52, 745-753.	1.8	8
4	Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation. Journal of Gastroenterology, 2022, 57, 486-494.	2.3	5
5	New role for hepatitis medical care coordinator training course proposed by Aichi Dental Association. Acta Hepatologica Japonica, 2022, 63, 346-349.	0.0	0
6	Present status of hepatitis medical care coordinators in regional core centers in Japan. Acta Hepatologica Japonica, 2021, 62, 96-98.	0.0	3
7	Novel strategies for the early diagnosis of hepatitisÂB virus reactivation. Hepatology Research, 2021, 51, 1033-1043.	1.8	12
8	Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. Journal of Hepatology, 2021, 75, 302-310.	1.8	56
9	Design and outcome of a novel strategy against viral hepatitis, developed by Aichi Dental Association. Acta Hepatologica Japonica, 2021, 62, 588-589.	0.0	2
10	Reply to: "Understanding HBcrAg components improves the interpretation of clinical HBcrAg assay results― Journal of Hepatology, 2021, 75, 998-999.	1.8	3
11	Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms, 2021, 9, 2083.	1.6	16
12	Cross-Protection of Hepatitis B Vaccination among Different Genotypes. Vaccines, 2020, 8, 456.	2.1	29
13	Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. International Journal of Molecular Sciences, 2020, 21, 949.	1.8	26
14	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatology Research, 2020, 50, 840-852.	1.8	46
15	Novel biomarkers for the management of chronic hepatitis B. Clinical and Molecular Hepatology, 2020, 26, 261-279.	4.5	79
16	The Role of Hepatitis B Core-Related Antigen. Genes, 2019, 10, 357.	1.0	40
17	Clinical Evaluation of a Newly Developed Chemiluminescent Enzyme Immunoassay for Hepatitis C Virus Core Antigen in Japan. Japanese Journal of Infectious Diseases, 2019, 72, 285-291.	0.5	1
18	Clinical usefulness of a newly developed high-sensitive hepatitis B surface antigen (HBsAg) assay for monitoring hepatitis B reactivation. Acta Hepatologica Japonica, 2019, 60, 237-247.	0.0	5

#	Article	IF	CITATIONS
19	In-depth interviews of non-hepatologists and the achievements made after introducing a "patient referral document for hepatitis" in our hospital. Acta Hepatologica Japonica, 2019, 60, 219-228.	0.0	1
20	High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. Journal of Gastroenterology, 2018, 53, 883-889.	2.3	33
21	Gut Dysbiosis Associated With Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 869-877.	2.9	130
22	Changes in serum lipid profiles caused by three regimens of interferonâ€free directâ€acting antivirals for patients infected with hepatitis C virus. Hepatology Research, 2018, 48, E203-E212.	1.8	26
23	Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker <i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein (WFA ⁺ -M2BP) in Chronic Hepatitis C with Advanced Fibrosis. Japanese Journal of Infectious Diseases, 2018, 71, 177-183.	0.5	5
24	Recommendation of medical consultation and/or treatment by pharmacists to patients with chronic hepatitis C who visited health insurance pharmacies. Acta Hepatologica Japonica, 2017, 58, 639-642.	0.0	2
25	Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PLoS ONE, 2017, 12, e0170667.	1.1	2
26	Hepatitis B virus and its sexually transmitted infection – an update. Microbial Cell, 2016, 3, 419-436.	1.4	76